Please activate JavaScript!
Please install Adobe Flash Player, click here for download

today Greater New York Dental Meeting Nov. 28, 2016

exhibitors 34 Greater New York Dental Meeting — Nov. 28, 2016 Ad By St. Renatus Staff n St. Renatus, LLC, a privately held company based in Fort Collins, Colo., recently announced it received U.S. Food and Drug Administration (FDA) approval on June 29 for its first product, a new dental anesthetic, Kovanaze™ (tetracaine HCl and oxymetazoline HCl) nasal spray. This is the first product that allows for dental anesthesia to be administered through a nasal spray without using a needle. “For more than 100 years, the dental industry has delivered den- tal anesthesia using a needle injec- tion. Now, through the efforts of a dedicated team, we have developed a revolutionary needle-free method for delivering regional anesthesia,” said Steve Merrick, St. Renatus’ CEO. Kovanaze is intended for dental use as a local anesthetic, delivered via nasal spray, to achieve regional anesthesia for restorative treatment of maxillary teeth 4-13 or A-J in patients 40 kg or more. To learn more about Kovanaze and order the product for your office, stop by Booth No. 5040 at the Greater New York Dental Meeting, visit www. kovanaze.com or call the Kovanaze Support Line at (800) 770-9400. St. Renatus touts FDA approval of Kovanaze nasal anaesthetic spray Here in New York To learn more about Kovanaze and order the product for your office, stop by booth No. 5040 at the Greater New York Dental Meeting. 5 Kovanaze: The first nasal anaesthetic spray, according to St. Renatus. (Photos/Provided by St. Renatus) ‘For more than 100 years, the dental industry has delivered dental anesthesia using a needle injection. Now, through the efforts of a dedicated team, we have developed a revolutionary needle-free method for delivering regional anesthesia.’

Pages Overview